Vaccines against drugs of abuse: Where are we now?

Therapeutic Advances in Vaccines

Volumn 2, Issue 4, 2014, Pages 106-117

  Kinsey, Berma ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antibodies; Drugs; Vaccines

Indexed keywords

EID: 84911498159     PISSN: 20510136     EISSN: None     Source Type: Journal    
DOI: 10.1177/2051013614537818     Document Type: Review

References (107)

1. Akbarzadeh, A., Mehraby, M., Zarbakhsh, M. and Farzaneh, H. (1999) Design and synthesis of a morphine-6-succinyl-bovine serum albumin hapten for vaccine development. Biotechnol Appl Biochem 30: 139–145
2. Akbarzadeh, A., Norousian, D., Farhangi, A., Mehrabe, M., Chiani, M., Zare, D. et al. (2009) Immunotherapy of 347 volunteer outpatient morphine addicts by human therapeutic morphine vaccine in Kermanshah province of Iran. J Pharmacol Toxicol 4: 30–35
3. American Lung Association (2013) Smoking. Available at: http://www.lung.org/stop-smoking/aboutsmoking/health-effects/smoking.html (accessed 19 May 2014).
4. American Society of Addiction Medicine (2008) Public policy statement on nicotine addiction and tobacco. Available at: http://www.asam.org (accessed 19 May 2014).
5. Anton, B. and Leff, P. (2006) A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 24: 3232–3240
6. Basmadjian, G., Singh, S., Sastrodjojo, B., Smith, B., Avor, K., Chang, F. et al. (1995) Generation of polyclonal catalytic antibodies against cocaine using transition state analogs of cocaine conjugated to diphtheria toxoid. Chem Pharm Bull (Tokyo) 43: 1902–1911
7. Berkman, C., Underiner, G. and Cashman, J. (1996) Synthesis of an immunogenic template for the generation of catalytic antibodies for (–)-cocaine hydrolysis. J Org Chem 61: 5686–5689
8. Biagini, R., Klincewicz, S., Henningsen, G., MacKenzie, B., Gallagher, J., Bernstein, D. et al. (1990) Antibodies to morphine in workers exposed to opiates etc. Life Sci 47: 897–908
9. Brand, R. (2013) Russell Brand on heroin, abstinence and addiction. Available at: http://www.spectator.co.uk/features/8857821/fixing-a-hole/ (accessed 19 May 2014).
10. Brimijoin, S., Orson, F., Kosten, T., Kinsey, B., Shen, X., White, S. et al. (2013a) Anti-cocaine antibody and butyrylcholinesterase-derived cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and cocaine-induced locomotor activity in mice. Chem Biol Interact 25: 212–216
11. Brimijoin, S., Shen, X., Orson, F. and Kosten, T. (2013b) Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev Vaccines 12: 323–332
12. Byrnes-Blake, K., Carroll, F., Abraham, P. and Owens, S. (2001) Generation of anti-(+) methamphetamine antibodies is not impeded by (+) meth-amphetamine administration during active immunization of rats. Int Immunopharmacol 1: 329–338
13. Byrnes-Blake, K., Laurenzana, E., Carroll, F., Abraham, P., Gentry, W., Landes, R. et al. (2003) Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol 461: 119–128
14. Cai, X., Tsuchikama, K. and Janda, K. (2013a) Modulating cocaine vaccine potency through hapten fluorination. J Am Chem Soc 135: 2971−2974
15. Cai, X., Whitfield, T. and Hixon, M. (2013b) Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design. J Med Chem 56: 3701−3709
16. Carrera, M., Ashley, J., Hoffman, T., Isomura, S., Wirsching, P., Koob, G. et al. (2004) Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem 12: 563–570
17. Carrera, M., Ashley, J., Parsons, L., Wirsching, P., Koob G. and Janda, K. (1995) Suppression of psychoactive effects of cocaine by active vaccination. Nature 378: 727–730
18. Carrera, M., Ashley, J., Wirsching, P., Koob G. and Janda, K. (2001) A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci U S A 9: 1988–1992
19. Carrera, M., Ashley, J., Zhou, B., Wirsching, P., Koob, G. and Janda, K. (2000). Cocaine vaccines: Antibody protection against relapse in a rat model. Proc Natl Acad Sci U S A 97: 6202–6206
20. Carrera, M., Trigo, J., Wirsching, P., Roberts, A. and Janda, K. (2005) Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. Pharmacol Biochem Behav 81: 709–714
21. Carroll, F., Abraham, P., Gong, P., Pidaparthi, R., Blough, B., Yingni Chee, Y. et al. (2009) The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. J Med Chem 52: 7301–7309
22. Carroll, M., Zlebnik, N., Anker, J., Kosten, T., Orson, F., Shen, X. et al (2012) Combined cocaine hydrolase gene transfer and anti-cocaine vaccine synergistically block cocaine-induced locomotion. PLoS One 7: e43536
23. Cashman, J., Berman, C. and Underliner, G. (2000) Catalytic antibodies that hydrolyze (–)-cocaine obtained by a high-throughput procedure. J Pharm Exp Ther 293: 952–961
24. Castro, A., Monji, N., Ali, H., Yi, J., Bowman, E. and McKennis, H. (1980) Nicotine antibodies: comparison of ligand specificities of antibodies produced against two nicotine conjugates. Eur J Biochem 104: 331–340
25. Castro, A. and Prieto, I. (1975) Nicotine antibody production: comparison of two nicotine conjugates in different animal species. Biochem Biophys Res Commun 67: 583–589
26. Chandrakumar, N., Carron, C., Meyer, D., Beardsley, P., Nash, S., Tam, L. et al. (1993) Phenylphosphonate monoeaster analogs of cocaine: potential haptens for the generation of catalytic antibodies. Bioorq Med Chem Lett 3: 309–331
27. Chen, X., Pravetoni, M., Bhayana, B., Pentel, P. and Wua, M. (2012) High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Vaccine 31: 159–164
28. Cheng, L., Kim, S., Chung, A. and Castro, A. (1973) Amphetamines: new radioimmunoassay. FEBS Lett 36: 339–342
29. Choi, J., Choi, M., Kim, C., Cho, Y., Chin, J. and Joi, Y. (1997) The optimization of ELISA for methamphetamine determination: the effect of immunogen, tracer and antibody purification method on the sensitivity. Arch Pharm Res 20: 46–52
30. Choi, J., Kim, C. and Choi, M. (1998) Immunological analysis of methamphetamine antibody and its use for the detection of methamphetamine by capillary electrophoresis with laser-induced fluorescence. J Chromatography B 705: 277–282
31. Choi, M., Gorovitz, B., Choi, J., Song, E., Nam, K. and Park, J. (1994) A visual immunoassay for the detection of methamphetamine using an enzymelabeled tracer derived from methamphetamine and amphetamine. Biol Pharm Bull 17: 875–880
32. Danger, Y., Gadjou, C., Devys, A., Galons, H., Blanchard, D. and Follea, G (2006) Development of murine monoclonal antibodies tomethamphetamine and methamphetamine analogues. J Immunol Method 309: 1–10
33. De, B., Pagovich, O., Hicks, M., Rosenberg, J., Moreno, A., Janda, K. et al. (2013) Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity. Hum Gene Ther 24: 58
34. Deng, S., de Prada, P. and Landry, D. (2002) Anticocaine catalytic antibodies. J Immunol Method 269: 299–310.
35. de Villiers, S., Cornish, K. and Troska, A. (2013) Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine 31: 6185–6193.
36. de Villiers, S., Lindblom, N., Kalayanov, G., Gordon, S., Baraznenok, I., Malmerfelt, A. et al. (2010) Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure. Vaccine 28: 2161–2168
37. Drugfreeworld (2013) Drug facts. Available at: http://www.drugfreeworld.org/drugfacts/crystalmeth/history-of-methamphetamine.html (accessed 19 May 2014).
38. Ettinger, R., Ettinger, W. and Harless, W. (1997) Active immunization with cocaine–protein conjugate attenuates cocaine effects. Pharmacol Biochem Behav 58: 215–220
39. Farhangi, A., Akbarzadeh, A., Mehrabi, M., Chiani, M., Saffari, Z., Mortazavi, M. et al. (2012) Immunotherapy of 436 morphine addicts by therapeutic morphine vaccine in Kerman province (I.R. Iran). J Vaccines Vaccin 2: 117
40. Farrell, M., Ward, J., Mattick, R., Hall, W., Stimson, G., des Jarlais, D. et al. (1994) Methadone maintenance treatment in opiate dependence: a review. Br Med J 309: 997–1001
41. Fox, B. (1997) Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Dependence 48: 153–158
42. Fox, B., Kantak, K., Edwards, M., Black, K., Bollinger, B., Botka, A. et al. (1996) Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 2: 1129–1132
43. Gao, Y. and Brimijoin, S. (2009) Lasting reduction of cocaine action in neostriatum – a hydrolase gene therapy approach. J Pharmacol Exp Ther 330: 449–457
44. Gao, Y., Geng, L., Orson, F., Kinsey, B., Kosten, T., Shen, X. et al. (2013) Effects of anti-cocaine vaccine and viral gene transfer of cocaine hydrolase in mice on cocaine toxicity including motor strength and liver damage. Chem Biol Interact 25: 208–211
45. Gao, Y., Orson, F., Kinsey, B., Kosten, T. and Brimijoin, S. (2010) The concept of pharmacologic cocaine interception as a treatment for drug abuse. Chem Biol Interact 187: 421–424
46. Haney, M., Gunderson, E., Jiang, H., Collins, E. and Foltin, R. (2010) Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 67: 59–65
47. Hartmann-Boyce, J., Cahill, K., Hatsukami, D. and Cornuz, J. (2012) Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev 8: CD007072
48. Henningfield, J. (1994) Relative addictiveness of drugs. Available at: http://www.drugsense.org/tfy/addictvn.htm (accessed 19 May 2014).
49. Hicks, M., De, B, Rosenberg, J., Davidson, J., Moreno, A., Janda, K. et al. (2011) Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol Ther 19: 612–619
50. Hieda, Y., Keyler, D., Ennifar, S., Fattom, A. and Pentel P. (2000) Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 22: 809–819
51. Hieda, Y., Keyler, D. and Van de Voort, J. (1999) Immunization of rats reduces nicotine distribution to brain. Psychopharmacology 143: 150–157
52. Hieda, Y., Keyler, D., Van de Voort, J., Kane, J., Ross, C., Raphael, D. et al. (1997) Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther 283: 76–81
53. Hill, J., Wainer, B., Fitch, F. and Rothberg, R. (1975) Delayed clearance of morphine from the circulation of rabbits immunized with morphine- 6-hemisuccinate bovine serum albumin. J Immunol 114: 1363–1368
54. Hu, Y., Zhen, H., Huang, W. and Zhang, C. (2014) A novel and efficient nicotine vaccine using nanolipoplex as a delivery vehicle. Hum Vaccines Immunother 10: 1–9
55. Ino, A., Dickerson, T. and Janda, K. (2007) Positional linker effects in haptens for cocaine immunopharmacotherapy. Bioorg Med Chem Lett 17: 4280–4283
56. Isomura, S., Wirsching, P. and Janda, K. (2001) An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis. J Org Chem 66: 4115–4121
57. Kantak, K., Collins, S., Bond, J. and Fox, B. (2001) Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology 153: 334–340
58. Kantak, K., Collins, S., Lipman, E., Bond, J., Giovanoni, K. and Fox, B. (2000) Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology 148: 251–262
59. Keyler, D., Hieda, Y., St Peter, J. and Pentel, P. (1999). Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tobacco Res 1: 241–249
60. Keyler, D., Roiko, S., Earley, C., Murtaugh, M. and Pentel, P. (2008) Enhanced immunogenicity of a bivalent nicotine vaccine. Int Immunopharmacology 8: 1589–1594
61. Koob, G., Hicks, M., Wee, S., Rosenberg, J., De, B., Kaminsky, S. et al. (2011) Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus. CNS Neurol Disord Drug Targets 10: 899–904
62. Kosten, T. and Domingo, C. (2013) Can you vaccinate against substance abuse? Expert Opin Biol Ther 13: 1093–1097
63. Kosten, T., Rosen, M., Bond, J., Settles, M., Roberts, J., Shields, J. et al. (2002) Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20: 1196–1204
64. Kosten, T., Shen, X., O’Malley, P., Kinsey, B., Lykissa, E., Orson, F. et al. (2013) A morphine conjugate vaccine attenuates the behavioral effects morphine in rats. Prog Neuropsychopharmacol Biol Psychiatry 45: 223–229
65. Landry, D., Zhao, K., Yang, G., Glickman, M. and Georgiadis, T. (1993) Antibody-catalyzed degradation of cocaine. Science 259: 1898–1901
66. Langone, J., Gjika, H. and Van Vunakis, H. (1973) Nicotine and its metabolites. Radioimmunoassays for nicotine and cotinine. Biochemistry 12: 5025–5030
67. Li, Q., Luo, Y., Sun, C., Xue, Y., Zhu, W., Shi, H. et al. (2011) A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats. J Neurochem 119: 1271–1281
68. Lockner, J., Ho, S., McCague, K., Chiang, S., Do, T., Fujii, G. et al. (2013) Enhancing nicotine vaccine immunogenicity with liposomes. Bioorg Med Chem Lett 23: 975–978
69. Maoz, A., Hicks, M., Vallabhjosula, S., Synan, M., Kothari, P., Dyke, J. et al. (2013) Adenovirus capsidbased anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter. Neuropsychopharmacology 38: 2170–2178
70. Martell, B., Mitchell, E. and Poling, J. (2005) Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 58: 158–164
71. Martell, B., Orson, F. and Poling, J. (2009) Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 66: 1116–1123
72. Matsukura, S., Sakamoto, N. and Imura, H. (1975) Radioimmunoassay of nicotine. Biochem Biophys Res Commun 64: 574–580
73. Matsushita, H., Noguchi, M. and Tamaki, E. (1974) Conjugate of bovine serum albumin with nicotine. Biochem Biophys Res Commun 57: 1006–1010
74. Maxwell, J. (2011) The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev 30: 264–270
75. McCluskie, M., Pryde, D., Gervais, D., Stead, D., Zhang, N., Benoit M. et al. (2013) Enhancing immunogenicity of a 3’aminomethylnicotine-DTconjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. Int Immunopharmacol 16: 50–56
76. McKenzie, K., Mee, J. and Rogers, C. (2007) Identification and characterization of single chain anti-cocaine catalytic antibodies. J Mol Biol 365: 722–731
77. McMillan, D., Hardwick, W., Li, M., Gunnell, M., Carroll, F., Abraham, P. et al. (2004) Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine selfadministration in the rat. J Pharm Exper Ther 309: 1248–1255
78. McMillan, D., Hardwick, W., Li, M. and Owens, S. (2002) Pharmacokinetic antagonism of (.)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody. Behav Pharmacol 13:465–473
79. Meijler, M., Matsushita, M. and Altobell III, L. (2003) A new strategy for improved nicotine vaccines using conformationally constrained haptens. J Am Chem Soc 125: 7164–7165
80. Mets, B., Winger, G., Cabrera, C., Seo, S., Jamdar, S., Yang, G. et al. (1998) A catalytic antibody against cocaine prevents cocaine’s reinforcing and toxic effects in rats. Proc Natl Acad Sci U S A 95: 10176–10181
81. Miller, M., Moreno, A., Aarde, S., Creehan, K., Vandewater, S., Vaillancourt, B. et al. (2013) A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats. Biol Psychiatry 73: 721–728
82. Moreno, A., Azar, M. and Warren, N. (2010) A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol Pharm 7: 431–441
83. Nabi (2011) News release. Available at: http://www.dddmag.com/news/2012/10/nabi-nicotine-vaccinefails-again
84. Nawrot, P., Jordan, S., Eastwood, J., Rotstein, J., Hugenholtz, A. and Feeley, M. (2003) Effects of caffeine on human health. Food Additive Contaminant 20: 1–5
85. NIAAA (2004) News release. http://www.niaaa.nih.gov/news-events/news-releases/alcohol-abuseincreases-dependence-declines-across-decade-youngadult (accessed 19 May 2014).
86. NIDA (2012) Drug facts. Available at: http://www.drugabuse.gov/publications/term/160/DrugFacts (accessed 19 May 2014).
87. NIDA (2013) Anti-drug vaccine animation. Available at: http://www.drugabuse.gov/news-events/nida-notes/anti-drug-vaccine-animation (accessed 19 May 2014).
88. Owens, S., Atchley, W., Hambuchen, M., Peterson, E. and Gentry, W. (2011) Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. CNS Neurol Disord Drug Targets 10: 892–898
89. Pentel, P., Malin, D., Ennifar, S., Hieda, Y., Keyler, D., Lake, J. et al. (2000) A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 65: 191–198
90. Peterson, E., Gunnel, M., Che, Y., Goforth, R., Carroll, F., Henry, R. et al. (2007) Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J Pharmacol Exp Ther 322: 30–39
91. Pravetoni, M., Keyler, D., Pidaparthi, R., Carroll, F., Runvon, S., Murtaugh, M. et al. (2012) Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol 83: 543–550
92. Pravetoni, M., Le Naour, M., Tucker, A., Harmon, T., Hawley, T., Portoghese, P. et al. (2013) Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. J Med Chem 56: 915–923
93. Procon (2013) http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881
94. Raupach, T., Hoogsteder, P. and van Schayck, C. (2012) Nicotine vaccines to assist with smoking cessation. Drugs 72: e1–e16
95. Rosenberg, J., De, B., Hicks, M., Janda, K., Kaminsky, S., Worgall, S. et al. (2013) Suppression of nicotineinduced pathophysiologyein by an adenovirus hexon-based antinicotine vaccine. Hum Gene Ther 24: 595–603
96. Rüedi-Bettschen, D., Wood, S., Gunnell, M., West, C., Pidaparthi, R., Carroll, F. et al. (2013) Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food. Vaccine 31: 4596–602
97. Ryan, J., Parker, C. and Williams, R. (1972) gamma- Globulin binding of morphine in heroin addicts. J Lab Clin Med 80: 155–184
98. Sakurai, M., Wirsching, P. and Janda, K. (1996) Design and synthesis of a cocaine-diamide hapten for vaccine development. Tetrahedron Lett 37: 5479–5482
99. Satoskar, S., Keyler, D., LeSage, M., Raphael, D., Ross, C., Pentel, P. et al. (2003) Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int Immunopharmacol 3: 957–970
100. Schlosburg, J., Vendruscoloa, L., Bremer, P., Lockner, J., Wade, C., Nunes, A. et al. (2013) Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci U S A 110: 9036–9041
101. Shen, X., Kosten, T., Lopez, A., Kinsey, B., Kosten, T., Orson, F. et al. (2013) A vaccine against methamphetamine attenuates its behavioral effects in mice. Drug Alcohol Dependence 129: 41–48
102. Singh, R., Kosten, T., Kinsey, B., Shen, X., Lopez, A., Kosten, T. et al. (2012) Dose-dependent changes in the locomotor responses to methamphetamine in BALB/cmice: low doses induce hypolocomotion. Pharmacol Biochem Behav 103: 230–236
103. Spector, S. and Parker, C. (1970) Morphine: radioimmunoassay. Science 168: 1347–1348
104. Stowe, G., Vendruscolo, L., Edwards, S., Schlosburg, J., Misra, K., Schulteis, G. et al. (2011) A vaccine strategy that induces protective immunity against heroin. J Med Chem 54: 5195–5204
105. Tonstad, S., Heggen, E. and Giljam, H. (2013) Niccine®, a nicotine vaccine, for relapse prevention: a phase ii, randomized, placebo-controlled, multicenter clinical trial. Nicotine Tobacco Res 15: 1492–501
106. Wee, S., Hicks, M., De, B., Rosenberg, J., Moreno, A., Kaminsky, S. et al. (2012) Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology 37: 1083–1091
107. Yang, G., Chun, J., Arakawa-Uramoto, H., Wang, X., Gawinowicz, M., Zhao, K. et al. (1996) Anticocaine catalytic antibodies: a synthetic approach to improved antibody diversity. J Am Chem Soc 118: 5881–5890.